IRIS Accounts Production v25.1.4.42 11216286 Board of Directors 1.4.24 31.3.25 31.3.25 false true false false false true false iso4217:GBP iso4217:USD iso4217:EUR xbrli:shares xbrli:pure utr:tonnes utr:kWh 11216286 2024-03-31 11216286 2025-03-31 11216286 2024-04-01 2025-03-31 11216286 2023-03-31 11216286 2023-04-01 2024-03-31 11216286 2024-03-31 11216286 ns15:EnglandWales 2024-04-01 2025-03-31 11216286 ns14:PoundSterling 2024-04-01 2025-03-31 11216286 ns10:Director1 2024-04-01 2025-03-31 11216286 ns10:PrivateLimitedCompanyLtd 2024-04-01 2025-03-31 11216286 ns10:SmallEntities 2024-04-01 2025-03-31 11216286 ns10:AuditExempt-NoAccountantsReport 2024-04-01 2025-03-31 11216286 ns10:SmallCompaniesRegimeForDirectorsReport 2024-04-01 2025-03-31 11216286 ns10:SmallCompaniesRegimeForAccounts 2024-04-01 2025-03-31 11216286 ns10:FullAccounts 2024-04-01 2025-03-31 11216286 1 2024-04-01 2025-03-31 11216286 ns10:Director2 2024-04-01 2025-03-31 11216286 ns10:RegisteredOffice 2024-04-01 2025-03-31 11216286 ns5:CurrentFinancialInstruments 2025-03-31 11216286 ns5:CurrentFinancialInstruments 2024-03-31 11216286 ns5:Non-currentFinancialInstruments 2025-03-31 11216286 ns5:Non-currentFinancialInstruments 2024-03-31 11216286 ns5:ShareCapital 2025-03-31 11216286 ns5:ShareCapital 2024-03-31 11216286 ns5:RetainedEarningsAccumulatedLosses 2025-03-31 11216286 ns5:RetainedEarningsAccumulatedLosses 2024-03-31 11216286 ns5:NetGoodwill 2024-04-01 2025-03-31 11216286 ns5:IntangibleAssetsOtherThanGoodwill 2024-04-01 2025-03-31 11216286 ns5:NetGoodwill 2024-03-31 11216286 ns5:NetGoodwill 2025-03-31 11216286 ns5:NetGoodwill 2024-03-31 11216286 ns5:LandBuildings 2024-03-31 11216286 ns5:PlantMachinery 2024-03-31 11216286 ns5:LandBuildings 2024-04-01 2025-03-31 11216286 ns5:PlantMachinery 2024-04-01 2025-03-31 11216286 ns5:LandBuildings 2025-03-31 11216286 ns5:PlantMachinery 2025-03-31 11216286 ns5:LandBuildings 2024-03-31 11216286 ns5:PlantMachinery 2024-03-31 11216286 ns5:WithinOneYear ns5:CurrentFinancialInstruments 2025-03-31 11216286 ns5:WithinOneYear ns5:CurrentFinancialInstruments 2024-03-31 11216286 ns5:BetweenOneTwoYears ns5:Non-currentFinancialInstruments 2025-03-31 11216286 ns5:BetweenOneTwoYears ns5:Non-currentFinancialInstruments 2024-03-31 11216286 ns5:Non-currentFinancialInstruments ns5:BetweenTwoFiveYears 2025-03-31 11216286 ns5:Non-currentFinancialInstruments ns5:BetweenTwoFiveYears 2024-03-31 11216286 ns5:Non-currentFinancialInstruments ns5:MoreThanFiveYears 2025-03-31 11216286 ns5:Non-currentFinancialInstruments ns5:MoreThanFiveYears 2024-03-31 11216286 ns5:WithinOneYear 2025-03-31 11216286 ns5:WithinOneYear 2024-03-31 11216286 ns5:BetweenOneFiveYears 2025-03-31 11216286 ns5:BetweenOneFiveYears 2024-03-31 11216286 ns5:MoreThanFiveYears 2025-03-31 11216286 ns5:MoreThanFiveYears 2024-03-31 11216286 ns5:AllPeriods 2025-03-31 11216286 ns5:AllPeriods 2024-03-31 11216286 ns5:DeferredTaxation 2024-03-31 11216286 ns5:DeferredTaxation 2024-04-01 2025-03-31 11216286 ns5:DeferredTaxation 2025-03-31 11216286 ns5:RetainedEarningsAccumulatedLosses 2024-03-31 11216286 ns5:RetainedEarningsAccumulatedLosses 2024-04-01 2025-03-31

REGISTERED NUMBER: 11216286 (England and Wales)

| Unaudited Financial Statements |

| for the Year Ended 31 March 2025 |

| for |

| PHARMACO HALESOWEN LIMITED |

PHARMACO HALESOWEN LIMITED (REGISTERED NUMBER: 11216286) |

Contents of the Financial Statements

for the Year Ended 31 March 2025

Page |

| Company Information | 1 |

| Balance Sheet | 2 |

| Notes to the Financial Statements | 4 |

| PHARMACO HALESOWEN LIMITED |

Company Information

for the Year Ended 31 March 2025

| DIRECTORS: | Mushtaq J Ismail

| Hasnain Fidahussein Asaria

| REGISTERED OFFICE: | Unit 4, Boultbee Business Units

| Nechells Place

| Birmingham

| West Midlands

| B7 5AR

| REGISTERED NUMBER: | 11216286 (England and Wales)

| ACCOUNTANTS: | Brindleys Limited

| 2 Wheeleys Road

| Edgbaston

| Birmingham

| West Midlands

| B15 2LD

PHARMACO HALESOWEN LIMITED (REGISTERED NUMBER: 11216286) |

Balance Sheet

31 March 2025

| 2025 | 2024 |

| Notes | £ | £ | £ | £ |

FIXED ASSETS

Intangible assets | 4 | 238,857 |  | 298,517 |  |

Tangible assets | 5 | 1,447 |  | 1,760 |  |

240,304 |  | 300,277 |  |

CURRENT ASSETS

Stocks | 6 | 26,903 |  | 32,188 |  |

Debtors | 7 | 114,147 |  | 101,933 |  |

Cash at bank and in hand | 100,793 |  | 172,555 |  |

241,843 |  | 306,676 |  |

CREDITORS

Amounts falling due within one year | 8 | 259,164 |  | 318,858 |  |

NET CURRENT LIABILITIES | (17,321 | ) | (12,182 | ) |

TOTAL ASSETS LESS CURRENT LIABILITIES | 222,983 |  | 288,095 |  |

CREDITORS

Amounts falling due after more than one year | 9 | (121,225 | ) | (228,619 | ) |

PROVISIONS FOR LIABILITIES | 11 | - |  | (440 | ) |

NET ASSETS | 101,758 |  | 59,036 |  |

CAPITAL AND RESERVES

Called up share capital | 100 |  | 100 |  |

Retained earnings | 12 | 101,658 |  | 58,936 |  |

101,758 |  | 59,036 |  |

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 March 2025.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 March 2025 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:

(a) | ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and

(b) | preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

PHARMACO HALESOWEN LIMITED (REGISTERED NUMBER: 11216286) |

Balance Sheet - continued

31 March 2025

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 8 September 2025 and were signed on its behalf by:

Mushtaq J Ismail - Director

PHARMACO HALESOWEN LIMITED (REGISTERED NUMBER: 11216286) |

Notes to the Financial Statements

for the Year Ended 31 March 2025

1. | STATUTORY INFORMATION

| Pharmaco Halesowen Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2. | ACCOUNTING POLICIES

| Basis of preparing the financial statements

| These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

| Turnover

| Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

| Goodwill

| Goodwill, being the amount paid in connection with the acquisition of a business in 2019, is being amortised evenly over its estimated useful life of ten years.

| Intangible assets

| Intangible assets are initially measured at cost. After initial recognition, intangible assets are measured at cost less any accumulated amortisation and any accumulated impairment losses.

| Tangible fixed assets

| Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.

| Motor Vehicle - 25% on reducing balance

| Stocks

| Stocks are valued at the lower of cost and net realisable value, after making due allowance for obsolete and slow moving items.

| Taxation

| Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

| Current or deferred taxation assets and liabilities are not discounted.

| Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

| Deferred tax

| Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

| Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

| Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

PHARMACO HALESOWEN LIMITED (REGISTERED NUMBER: 11216286) |

Notes to the Financial Statements - continued

for the Year Ended 31 March 2025

2. | ACCOUNTING POLICIES - continued

| Pension costs and other post-retirement benefits

| The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

3. | EMPLOYEES AND DIRECTORS

| The average number of employees during the year was 9 (2024 - 7 ) .

4. | INTANGIBLE FIXED ASSETS

| Goodwill

£ |

| COST

| At 1 April 2024

| and 31 March 2025 | 596,604 |  |

| AMORTISATION

| At 1 April 2024 | 298,087 |  |

| Charge for year | 59,660 |  |

| At 31 March 2025 | 357,747 |  |

| NET BOOK VALUE

| At 31 March 2025 | 238,857 |  |

| At 31 March 2024 | 298,517 |  |

5. | TANGIBLE FIXED ASSETS

| Plant and |

| Land and |  | machinery |

| buildings |  | etc |  | Totals

£ | £ | £ |

| COST

| At 1 April 2024

| and 31 March 2025 | 1 |  | 3,978 |  | 3,979 |  |

| DEPRECIATION

| At 1 April 2024 | 1 |  | 2,218 |  | 2,219 |  |

| Charge for year | - |  | 313 |  | 313 |  |

| At 31 March 2025 | 1 |  | 2,531 |  | 2,532 |  |

| NET BOOK VALUE

| At 31 March 2025 | - |  | 1,447 |  | 1,447 |  |

| At 31 March 2024 | - |  | 1,760 |  | 1,760 |  |

PHARMACO HALESOWEN LIMITED (REGISTERED NUMBER: 11216286) |

Notes to the Financial Statements - continued

for the Year Ended 31 March 2025

6. | STOCKS

2025 | 2024 |

£ | £ |

| Stocks | 26,903 |  | 32,188 |  |

7. | DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR |

2025 | 2024 |

£ | £ |

| Trade debtors | 89,894 |  | 83,374 |  |

| Other debtors | - |  | 3,219 |  |

| VAT | 22,556 |  | 13,625 |  |

| Prepayments | 1,697 |  | 1,715 |  |

114,147 |  | 101,933 |  |

8. | CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR |

2025 | 2024 |

£ | £ |

| Bank loans and overdrafts | 11,828 |  | 17,005 |  |

| Trade creditors | 126,046 |  | 135,575 |  |

| Amounts owed to group undertakings | 41,441 |  | 66,441 |  |

| Tax | 33,970 |  | 29,180 |  |

| Social security and other taxes | 523 |  | - |  |

| Other creditors | 170 |  | 564 |  |

| Directors' current accounts | 38,373 |  | 63,460 |  |

| Accrued expenses | 6,813 |  | 6,633 |  |

259,164 |  | 318,858 |  |

9. | CREDITORS: AMOUNTS FALLING DUE AFTER MORE THAN ONE YEAR |

2025 | 2024 |

£ | £ |

| Bank loans - 1-2 years | 11,828 |  | 17,005 |  |

| Bank loans - 2-5 years | 35,485 |  | 51,015 |  |

| Bank loans more 5 yr by instal | 73,912 |  | 160,599 |  |

121,225 |  | 228,619 |  |

| Amounts falling due in more than five years:

| Repayable by instalments

| Bank loans more 5 yr by instal | 73,912 |  | 160,599 |  |

PHARMACO HALESOWEN LIMITED (REGISTERED NUMBER: 11216286) |

Notes to the Financial Statements - continued

for the Year Ended 31 March 2025

10. | LEASING AGREEMENTS

| Minimum lease payments under non-cancellable operating leases fall due as follows:

2025 | 2024 |

£ | £ |

| Within one year | 9,500 |  | 9,500 |  |

| Between one and five years | 38,000 |  | 38,000 |  |

| In more than five years | 40,692 |  | 50,192 |  |

88,192 |  | 97,692 |  |

11. | PROVISIONS FOR LIABILITIES

2025 | 2024 |

£ | £ |

| Deferred tax | - |  | 440 |  |

| Deferred |

| tax |

£ |

| Balance at 1 April 2024 | 440 |  |

| Provided during year | (440 | ) |

| Balance at 31 March 2025 | - |  |

12. | RESERVES

| Retained

| earnings

£ |

| At 1 April 2024 | 58,936 |  |

| Profit for the year | 42,722 |  |

| At 31 March 2025 | 101,658 |  |